Six programs addressing significant market opportunities.
Six programs spanning oncology and metabolic disease. Internal small molecules and antibodies on first-in-class targets; partnered campaigns with global pharma. Every program is built on an EMP-stabilised receptor.
- GPR75ObesitySmall moleculeIn vitro Lead — 2H 2026
- GPR87NSCLC, Head & NeckmAb (ADCC or ADC)In vivo POC — 1H 2027
- GPR81PDAC, TNBCmAbIn vivo POC — 1H 2027
- MultipleMultiplemAb / ADCIn vivo POC
- CCR8CRC, SCLC, othersmAbPartnering activities ongoing
- Undisclosed w/ OrionUndisclosedmAbPartnered at discovery stage
How we pick programs.
- 01
Difficult-to-drug, high-value multi-span membrane proteins where EMP™ technology solves a meaningful challenge.
- 02
Strong genetic and/or mechanistic evidence linking the target to disease.
- 03
Genetic validation in defined patient subpopulations, with potential for expansion into large markets.
- 04
A mix of historically undruggable targets and first-in-class / best-in-class opportunities.
A genetically validated obesity target — finally tractable.
Loss-of-function mutations in GPR75 strongly correlate with lower obesity risk in humans. Until now, the receptor was an orphan GPCR that defied screening. Abilita's EMP™ unlocked discovery of multiple small-molecule families and a cryo-EM structure; lead candidates are expected in 2H 2026.
First-in-class programs targeting tumour survival and metabolism.
GPR87 is a tumour-associated GPCR highly expressed in NSCLC and head & neck cancer; GPR81 is a lactate-sensing receptor implicated in pancreatic and triple-negative breast cancer. Both have been stabilised by EMP™ and are in antibody-discovery campaigns toward in vivo POC in 1H 2027.